How do the latest checkpoint inhibitors work for pancreatic cancer? Are there specific biomarkers that are relevant...
Checkpoint inhibitors are a type of immunotherapy that has shown some promise in treating certain cases of pancreatic cancer. Here's an overview of how they work and relevant biomarkers:
How Checkpoint Inhibitors Work in Pancreatic Cancer:
- These drugs, like pembrolizumab and nivolumab, work by blocking proteins called PD-1 or PD-L1 that prevent the immune system from attacking cancer cells.
- By blocking this "checkpoint", it allows the patient's own immune cells to better recognize and attack the pancreatic cancer cells.
- However, pancreatic cancer is considered a "cold" tumor with relatively low mutation burden, making it less responsive to single-agent checkpoint inhibitors.
Relevant Biomarkers:
- High tumor mutation burden (TMB) - More mutations make the cancer more visible to the immune system. High TMB may predict better response.
- PD-L1 expression - Cancers with higher PD-L1 levels may respond better to these drugs that block the PD-1/PD-L1 pathway.
- Mismatch repair deficiency (dMMR) - Defects in DNA mismatch repair genes lead to mutations that may make tumors more responsive.
While checkpoint inhibitors alone have limited benefit in pancreatic cancer so far, some of the latest approaches combine them with chemotherapy drugs and/or other immunotherapies in an attempt to make the cancer "hotter" and more responsive. Ongoing clinical trials are evaluating biomarker-based patient selection as well.
It's an area of active research, so I'd recommend discussing the latest options and criteria for treatment with your oncologist. Let me know if you need any clarification or have additional questions!
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- Latest treatment in pancreatic cancer
- How does immunotherapy work for cancer
- What are PARP inhibitors and who should take them
- T4N0M1 pancreatic adenocarcinoma of the uncinate process with liver metastases- what are the latest treatment...
- How do I find clinical trials for my specific cancer
- How do I interpret my biomarker test results
- What are the side effects of TKI inhibitors
- What is targeted therapy and how does it work for cancer